Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.61 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.61 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.61 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.61 |
| ▸ | CBFB | Q13951 | 1/20 | 0.61 |
| ▸ | TERT | O14746 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.47 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.46 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24527584 | 0.92 | MEN1 (0.52) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL24527582 | 0.85 | TERT (0.53) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL24527590 | 0.84 | KDM4E (0.45) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL28271344 | 0.82 | CA12 (0.47) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL6194854 | 0.82 | MEN1 (0.61) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL17432455 | 0.82 | MAP4K4 (0.46) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL3727450 | 0.82 | MEN1 (0.48) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL3727451 | 0.82 | MEN1 (0.48) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL25296906 | 0.81 | MGAM (0.47) | MEN1NPC1RAB9AKMT2AKDM4E | |
| SCHEMBL16260994 | 0.80 | ACSS2 (0.47) | MEN1NPC1RAB9AKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| WO-2022006439-A2 | COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-06 | — | — | WO | disclosed |
| US-7205311-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED | 2007-04-17 | — | — | US | disclosed |
| US-20050070568-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-03-31 | — | — | US | disclosed |
| EP-1474397-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | Cancer Research Technology Limited (GB) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003059885-A1 | THERAPEUTIC ACRIDONE AND ACRIDINE COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070568-A1 | Therapeutic acridone and acridine compounds | CCNK, TERT, CCNA1 | MEN1 1891/4885NPC1 1422/4885RAB9A 2371/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | MEN1 4843/4885NPC1 35/4885RAB9A 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.